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Abstract
Background—Approximately 200,000 kidney transplant recipients are living in the US; they are 
at increased risk for cardiovascular and other adverse outcomes. Biomarkers predicting these 
outcomes are needed. Using specimens collected during the FAVORIT (Folic Acid for Vascular 
Outcome Reduction In Transplantation) trial, we determined whether plasma levels of B-type 
natriuretic peptide (BNP) and cardiac troponin I are associated with adverse outcomes in stable 
kidney transplant recipients.
Methods—510 subjects were selected randomly from the 4110 FAVORIT participants. This 
cohort was then enriched for all additional subjects with adverse outcomes (death, dialysis-
dependent kidney failure and cardiovascular outcomes) for total 1131 participants studied. 
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Quartiles of BNP and high sensitivity cardiac troponin I (hs-cTnI) were included in adjusted 
models. Combinations of normal and elevated hs-cTnI (>26.2 ng/L) and BNP (>100 pg/mL) were 
also studied.
Results—Median concentrations and interquartile ranges were 5.6 (3.3, 10.5) ng/L for hs-cTnI 
and 39 (15, 94) pg/mL for BNP. Hazard ratios for each adverse outcome were higher with higher 
quartiles of BNP after adjustment and remained statistically significant after adding hs-cTnI to the 
model. The highest quartile hazard ratio for dialysis dependent kidney failure was 2.47 (95% CI 
1.21–5.05). Simultaneous elevations of BNP and hs-cTnI over clinical cutoffs were strongly 
associated with adverse outcomes with hazard ratios 8.8 (3.4–23.1) for dialysis dependent kidney 
failure and 6.3 (2.7–15.0) for cardiovascular outcomes.
Conclusions—Higher BNP is associated with mortality and cardiovascular and kidney 
outcomes in stable kidney transplant recipients. Elevated BNP and hs-cTnI identify candidates for 
targeted risk reduction.
INTRODUCTION
Approximately 17,000 kidney transplants are performed annually in the United States1 and 
about 70,000 annually worldwide.2 Currently, there are approximately 200,000 living kidney 
transplant recipients in the US (144,180 in 20093). Despite decreased glomerular filtration 
rate (GFR) in most kidney transplant recipients, mean 10-year graft survival ranges from 
34% to 48% in US patients and is as high as 56% in Europeans.4 Increasing graft survival 
underlies the fact that other chronic complications are increasingly important in this 
population. Both cardiovascular disease (CVD) and failure of the kidney transplant are 
common and have substantial impact on morbidity and mortality in this population. 
Biomarkers to identify kidney transplant recipients at increased risk for adverse outcomes 
may lead to improved management of these patients.
Natriuretic peptide and cardiac troponin I and T immunoassays have demonstrated 
remarkable ability not only to diagnose myocardial infarction and heart failure but also to 
predict multitude of adverse outcomes. The B-type natriuretic peptide (BNP) and the N-
terminal pro-B-type natriuretic peptide (NT-proBNP) have become established biomarkers 
of heart failure5 and cardiac troponins I (cTnI) and T are used for the diagnosis of acute 
myocardial infarction. However, elevations of cardiac troponins are not unique to acute 
myocardial infarction; they have been described in a number of additional acute and chronic 
conditions.6,7
Since BNP and NT-proBNP respond to volume overload, they are elevated in chronic kidney 
disease (CKD).8–10 Increased cTn levels have also been described in patients with CKD11, 
which can limit diagnostic utility of cTn assays for acute myocardial events in patients with 
decreased GFR12 but, at the same time, may underlie the reported predictive value of cTn for 
cardiac events and mortality in patients with CKD.13
However, whether these findings can be applied to kidney transplant recipients is not known. 
We conducted a case-cohort study of specimens collected from stable kidney transplant 
recipients during their participation in a clinical trial of homocysteine lowering, the Folic 
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Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial, to assess 
whether levels of BNP and hs-cTnI are associated with adverse outcomes.
METHODS
Subjects in the parent study
The FAVORIT trial was a randomized, multi-center, double-blind controlled trial conducted 
in stable kidney transplant recipients to evaluate whether a homocysteine-lowering vitamin 
intervention reduced the risk of cardiovascular events. The design and primary outcome of 
the trial has been described previously.14–16 Briefly, a total of 4110 stable kidney transplant 
recipients were enrolled from 2002 to 2007 and randomized to treatment with either a 
multivitamin with a high dose of folic acid (5.0 mg), vitamin B6 (pyridoxine, 50 mg), and 
vitamin B12 (cyanocobalamin, 1.0 mg) or a multivitamin with lower doses of vitamin B6 
(1.4 mg) and B12 (2.0 µg) and no folic acid. Individuals age 35–75 years who lived with a 
transplanted kidney for at least 6 months were screened for eligibility at 30 transplant 
centers located in the US, Canada, and Brazil. Inclusion criteria were an elevated serum 
homocysteine level (> 11 µmol/L for women and > 12 µmol/L for men) and stable kidney 
function (creatinine clearance of >30 mL/min in men and >25 mL/min in women).
Exposures
Risk of adverse outcomes was evaluated based on biomarker results categorized by two 
different methods; first, as quartiles of BNP and high sensitivity cardiac troponin I (hs-cTnI), 
and second, using clinically utilized cutoffs for hs-cTnI and BNP. Both methods were 
included in models adjusted for baseline age, gender, race, treatment assignment, history of 
smoking, coronary heart disease, diabetes, urine albumin/creatinine ratio (ACR), eGFR, 
BMI, blood pressure, lipid levels, graft vintage and donor type. Most of these variables were 
determined at baseline.
Outcomes
Cardiovascular outcomes studied were MI, hemorrhagic or non-hemorrhagic stroke, 
resuscitated sudden death, or cardiovascular death. These events were reviewed and 
adjudicated centrally, blinded to treatment group assignment. In our analysis, we considered 
these outcomes as a composite. Secondary outcomes were all-cause death and dialysis-
dependent kidney failure (DDKF), defined by a requirement for maintenance dialysis for at 
least 3 months or until a transplant is received. These outcomes were evaluated alone and 
combined with the cardiovascular composite outcome. Follow-up in-clinic visits were 
scheduled every 6 months and events of interest were ascertained through June 24, 2009. 
Cardiovascular death, MI, resuscitated sudden death and stroke were centrally reviewed and 
adjudicated by the Clinical Endpoints Committee; the remaining outcomes were identified 
through medical record abstraction. Over median follow-up of 3.9 years, there was no 
difference in the primary outcome between the two treatment groups, facilitating use of 
FAVORIT trial data for cohort analyses.16
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Selection of cases and subcohort
A case-cohort design is an efficient approach for analyzing failure times in a population 
where exposure information is not readily available for all subjects and clinically outcomes 
are relatively rare, and is considered more flexible than a case-control design.24 From the 
3530 FAVORIT participants with complete baseline data, including serum creatinine and 
lipid studies as well as urine albumin to creatinine ratio, we selected a random sample of 530 
(15%) stratified by treatment group assignment. The random sample included 136 FAVORIT 
participants who had at least one study outcome. This random sample was supplemented by 
‘cases’, specifically adding all additional 601 FAVORIT participants with adverse outcomes 
for a total of 737 subjects having one or more adverse outcome.
Baseline patient data
Baseline data included age, gender, race, treatment group, country, smoking status, medical 
history (CVD, hypertension, diabetes mellitus), transplant characteristics (living donor 
kidney, time since transplant), physical examination findings (body mass index (BMI), 
systolic and diastolic blood pressure), and laboratory variables (serum creatinine, 
homocysteine, serum total cholesterol, high density lipoprotein (HDL) cholesterol, low 
density lipoprotein (LDL) cholesterol, triglycerides, and urine albumin and creatinine). 
Previous CVD was defined as prior myocardial infarction, coronary artery revascularization, 
stroke, carotid artery revascularization, abdominal or thoracic aneurysm repair and/or lower 
extremity arterial revascularization based on participant self-report and medical records, if 
available. Serum creatinine was assayed in 2011 from frozen sera stored at −80° C obtained 
at the baseline study visit participants using an alkaline picrate kinetic method on an 
Olympus AU 400e (Olympus America Inc., Center Valley, PA) analyzer that was calibrated 
to an isotope dilution mass spectrometry (IDMS) traceable standard. GFR was estimated 
with the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 2009 creatinine 
equation.17 Self-reported race was categorized as white, black, or other; individuals who 
identified as “other” and the 27 individuals who had missing information were classified as 
white to estimate GFR. BMI was calculated as weight (kg)/height (m)2. Mean baseline 
eGFR of all study participants was 48.8 ± 16.2 mL/min/1.73 m2. Blood pressure was 
measured twice in a rested seated position and the values averaged. Hypertension was 
defined either by a systolic blood pressure >140 mmHg, diastolic >90 mmHg, or use of 
antihypertensive medication at study enrollment. LDL cholesterol was estimated using the 
Friedewald equation at triglyceride levels below 400 mg/dL and measured in the 234 
participants with triglyceride levels above 400 mg/dL. Diabetes was defined by patient 
medical history or the use of insulin or oral hypoglycemic medications.
Biomarker testing
Cardiac biomarkers were measured in previously unthawed baseline EDTA-anticoagulated 
plasma samples that had been stored at −80°C prior to assay. These specimens were thawed 
and centrifuged in batches immediately prior to testing on the Abbott Architect i2000SR 
immunoanalyzer (Abbott Diagnostics, Lake Forest, IL). Cardiac troponin was measured 
using an investigational high sensitivity cTnI (hs-cTnI) assay (Abbott ARCHITECT STAT 
High Sensitive Troponin-I). The reported limit of detection is 1.5 ng/L to 3 ng/L with 
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reported coefficient of variation (CV) of 10% from 5.6 ng/L18 to 7 ng/L.19 Recent analytic 
characterizations identified 99th percentiles ranging from 14.8 ng/L to 27.0 ng/L.18–21 We 
used the 99th percentile threshold of 26.2 ng/L, which is recommended in the assay package 
insert22, to define elevated hs-cTnI. BNP concentrations were measured using the 
commercially available Abbott ARCHITECT BNP assay. The assay range is 10–5,000 
pg/mL, with a CV of 4.4% at 92 pg/mL and 1.7% at 3,572 pg/mL. Although the reference 
range for BNP varies with sex and age, we used the commonly accepted single diagnostic 
cutoff of 100 pg/mL.23
Statistical Analyses
Statistical analyses accounted for the case-cohort design using the Barlow method for robust 
variance estimation.24,25 BNP and cTnI values for individuals in the random sample were 
categorized into quartiles for reporting baseline characteristics and for weighted proportional 
hazards modeling. The association of BNP and hs-cTnI concentrations with clinical 
outcomes was assessed with unadjusted and adjusted Cox regression models. Adjusted 
models included age, sex, race, multivitamin allocation, country, smoking, history of 
cardiovascular disease, diabetes mellitus, ACR, eGFR, BMI, blood pressure, lipid levels, 
graft vintage and donor type. These associations were examined for each cardiac biomarker 
alone and after adjustment for the other biomarker.
To determine the prognostic importance of simultaneous elevations of both biomarkers, we 
evaluated the highest quartiles of BNP and hs-cTnI combined with the three lowest quartiles. 
In addition, since clinical intervention is likely to be based on the detection of elevations of 
BNP or cTnI above the cut points of 100 pg/mL for BNP and 26.2 ng/L for hs-cTnI in use 
by most clinical laboratories, we evaluated combinations of low and elevated BNP and hs-
cTnI. We also tested for interaction between clinically elevated BNP and cTnI 
concentrations by including an interaction term in the Cox models denoting the 
simultaneous elevation of both biomarkers. P-values <0.05 were considered statistically 
significant. All analyses were conducted in SAS, Version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Study subjects
From 3530 participants potentially eligible for this case-cohort cohort substudy, 737 were 
identified as having one or more outcomes of interest, including 405 deaths, 293 DDKF 
events and 319 cardiovascular events. Among the randomly selected 530 participant sub-
cohort, 136 had at least one clinical outcome and, by definition were also included among 
the 737 participants with events, resulting in a total study population of 1,131 participants 
(Table 1 and Figure 1)
Baseline characteristics
Of the randomly selected 530 participant sub-cohort, 510 had complete data regarding hs-
cTnI, BNP, demographic information, and CVD history. Mean age of participants was 51.6 
± 9.2 years; 38% were women, 37% had diabetes, 19% had CVD, 42% received a living 
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donor kidney, and mean eGFR was 45.9 ± 18.2 ml/min/1.73 m2. Follow-up ranged from 0 to 
82 months with a mean of 4.0 ± 1.5 years.
Baseline characteristics by quartiles of hs-cTnI and BNP are summarized in Tables 2 and 3, 
respectively. The median (interquartile range) concentrations in the random cohort (n= 510) 
were 5.6 (3.3–10.5) ng/L for hs-cTnI and 39.4 (15.3–93.6) pg/mL for BNP. Of the total of 
1131 patients studied, 1111 (98.2%) had detectable cTnI concentrations. BNP was 
measurable in all participants. Of the 510 randomly sampled patients, 6% had cTnI 
concentrations greater than the recommended 99th percentile of 26.2 ng/L and 24% had 
values greater than the single-value cutoff of 100 pg/mL. Within the random cohort, higher 
BNP and hs-cTnI levels were significantly associated with older age, unrelated donor type, 
history of CVD and diabetes mellitus, higher systolic BP, lower eGFR and higher urine 
ACR. There was no association of sex, race, graft vintage, smoking, or BMI with either BNP 
or hs-cTnI within the subcohort.
BNP
Figure 1a shows the hazard ratios (HRs) for quartiles of BNP in the fully adjusted model and 
in the same model with an additional adjustment for the hs-cTnI. HRs for each fatal and 
nonfatal outcome were significantly higher with higher quartiles of BNP after adjustment 
and remained significant in the model which also included hs-cTnI.
hs-cTnI
The associations of outcomes with hs-cTnI quartiles (Figure 1b) were not as strong as those 
for BNP. Compared to BNP with a significant trend for all outcomes in the fully adjusted 
model, the trend for hs-cTnI across quartiles was significant for all-cause death either alone 
or in combination the cardiovascular composite outcome, or DDKF but not for DDKF and 
cardiovascular composite alone. The trend was no longer significant for either of the 
outcomes after adjustment for BNP concentrations.
BNP and hs-cTnI Combined – Quartile Approach
Sixty-three patients (12%) from the random cohort of 510 had both BNP and hs-cTnI in the 
highest quartile. HRs for adverse outcomes for these patients ranged from 2.46 (1.38–4.36) 
for cardiovascular outcomes to 3.34 (2.04–5.48) for mortality and DKKF. HRs for all four 
patient cohorts and for additional adverse outcomes are shown in the Supplemental Table 1.
BNP and hs-cTnI Combined – Diagnostic Cutoff Approach
A total of 17 patients (3%) from the random sample had both BNP and hs-cTnI levels which 
exceeded the clinically accepted thresholds. This number increased to 72 patients (6%) in 
the enriched population. In the adjusted models, point estimates suggested synergistic effects 
for all outcomes with significant interactions for DDKF (p=0.013) and the composite of all-
cause mortality and DDKF (p=0.03). Participants with both biomarker levels above the 
clinical cutoffs had an 8.8-fold increased risk of DDKF (HR 8.8; 3.4–23.1) compared to 
those with both biomarker values in the normal range. The hazard ratios for other adverse 
outcomes were all statistically significant and ranged from 6.3 to 7.9 (Figure 2 and 
Supplemental Table 2).
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Discussion
Despite the burden of CVD among kidney transplant recipients, few studies have examined 
the utility of biomarkers in these patients26. Using a case-cohort study design we found a 
statistically significant association of BNP and cTnI concentrations with clinical outcomes 
among stable kidney transplant recipients enrolled in a clinical trial of homocysteine 
lowering. Of note, BNP was more strongly associated with clinical outcomes than cTnI. The 
combinations of the two markers, either the highest quartiles, or a combination of clinically 
abnormal levels, were strongly associated with adverse outcomes.
In contrast to cTnI levels seen in patients after acute events27, cTnI concentrations in our 
population are similar to those observed in patients with stable CAD. Using the same assay 
as the one used in this study, Omland and coworkers assessed the prognostic value of cTnI in 
low-risk patients with stable CAD by measuring hs-cTnI levels at baseline in 3,623 patients 
with stable CAD. Similar to our results, 98.5% of their patients had detectable cTnI 
concentrations. After adjustment for conventional risk markers, hs-TnI levels in the fourth 
compared with the 3 lower quartiles were associated with an increased risk of cardiovascular 
death or HF (HR 1.84; 95% CI 1.30 to 2.61; p < 0.001).28
We and others have reported cTnI elevations in additional disease categories such as diabetes 
mellitus and CKD.10,29,30 Although these studies used assays different from the hs-cTnI 
assay used by us, a clear trend towards higher risk of adverse events with higher cTnI levels 
was observed.
We found that in our population of stable kidney transplant recipients the elevations above 
the diagnostic cutoff were more common for BNP. While 6% of randomly selected patients 
had elevated hs-cTnI levels, 24% of patients had BNP concentrations higher than the 
commonly used single cutoff of 100 pg/ml. This is not surprising since an increase in BNP 
in both early and advanced stages of CKD has been repeatedly described.31–33
We showed BNP to be a more consistent predictor of outcomes than hs-cTnI. This is most 
likely due to the fact that volume overload and circulatory stress lead to an earlier release of 
BNP from stretched cardiac myocytes, while the onset of ischemia and necrosis that elevate 
hs-cTnI concentrations may follow considerably later. Not surprisingly, the combined usage 
of BNP with hs-cTnI allowed for the identification of an even higher risk subgroup, with the 
patients with both biomarkers in the highest quartiles having HRs for adverse outcomes in 
the 2.46 to 3.34 range depending on the outcome studied.
The most informative result for clinicians is the prognostic information relating to elevation 
of biomarkers over diagnostic cutoffs. While elevated BNP alone is associated with 
increased risk for clinical events, simultaneous elevation of both BNP and cTnI increased 
hazard ratios for adverse outcomes 6.3–8.8 fold depending on the adverse outcomes studied, 
though the relatively small proportion of patients exceeding both thresholds results in wider 
confidence intervals.
Additional insight into event-free survival of our patients might be obtained by measuring 
BNP and cTnI concentrations in serial specimens and by correlating the annual rate of 
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change with outcomes. However, earlier work did not demonstrate a significant 
improvement of risk classification over the baseline levels. Roberts et al. followed BNP 
levels in 48 patients with CKD, in 102 dialysis patients, and in 73 kidney transplant 
recipients for over five years and concluded that while temporal changes in BNP were 
predictive of survival in CKD, they did not predict survival in dialysis patients and kidney 
transplant recipients.34 Similarly, Bodlaj et al. measured NT-proBNP in 76 kidney transplant 
recipients before, shortly after and 2–3 weeks after transplant and found that NT-proBNP 
levels measured 2–3 weeks after transplantation were significantly correlated with eGFR at 
1 year after transplantation.35 However, these two patient populations differ from our 
patients who are more remote from the actual kidney transplantation with a median graft 
vintage of 4.0 years. Both reports also study cohorts considerably smaller than our sample of 
1131 patients from a cohort of 3510; however both suggest that baseline levels of BNP may 
have the highest predictive value and that adding additional time points may be of limited 
additional benefit.
Continuing monitoring of kidney function has been and will remain the standard of care in 
kidney transplant recipients. At the same time, improved ability to predict increased risk of 
adverse outcomes may substantiate more frequent patient visits and monitoring, diet 
modification, tighter blood pressure control with earlier adjustment of vasodilators and 
diuretics, as well as adjustment of additional medications and other interventions aimed at 
improving graft and patient survival. Based on our data we suggest that an elevation in either 
BNP or cTnI concentration signals a moderately increased risk of adverse outcomes, while 
simultaneous elevation of both biomarkers is associated with a marked increase in risk and 
should potentially trigger more aggressive evaluation for and treatment of modifiable 
cardiovascular risk factors and manifestations.
Limitations and strengths
This is an observational study with a relatively small number of events; however, use of the 
case-cohort design enriched the population for clinically important outcomes while still 
allowing estimates of baseline prevalence of abnormal biomarker levels. Furthermore, we 
used single diagnostic cutoffs for both biomarkers instead of age- and gender-specific 
reference ranges. Finally, we only studied the baseline specimens and not the additional time 
points. We do not specifically know whether worsening HF manifestations or subclinical 
cardiac ischemia potentially identified by abnormal biomarker levels would be modifiable or 
were on the causal pathway to participant events. However, use of these biomarkers to 
identify high risk subsets within the kidney transplant population may facilitate future 
research and targeted interventions to reduce adverse outcomes in this group, which 
represents the largest cohort of stable kidney transplant recipients studied to date. In 
addition, our study evaluates the same outcomes as the FAVORIT trial itself.
Conclusions
Baseline BNP and hs-cTnI concentrations were associated with increased risk of adverse 
outcomes in stable kidney transplant recipients. Baseline BNP concentrations were 
associated with all-cause death, cardiovascular outcomes, as well as renal outcomes. BNP 
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was more strongly associated with adverse events in this particular patient population than 
cTnI, which had stronger association with all-cause mortality. Simultaneous elevation of 
both BNP and cTnI over the common diagnostic cutoffs was strongly associated with 
clinical outcomes.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Distribution of clinical outcomes in the 3530 patients with complete data sets
Venn diagram showing the distribution of adverse outcomes in 737 patients who experience 
at least one adverse outcome. Some patients experienced more than one clinical outcome.
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Figure 2. Quartiles of BNP and cTnI and adverse outcomes
BNP and cTnI concentrations were stratified by quartiles and hazard ratios for individual 
adverse outcomes were calculated before (circles) and after (squares) adding the other 
biomarker to the model.
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Figure 3. Adjusted hazard ratios for combinations of normal and elevated BNP and cTnI
Patients were stratified by BNP and hs-cTnI values below and above the clinical cutoff, i.e. 
100 pg/mL for BNP and 26.2 ng/L for hs-cTnI. Hazard ratios and their 95% confidence 
intervals for adverse outcomes are shown.
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Table 1
Case-cohort design–number of subjects and events available for each clinical outcome
Clinical Outcome Subjects Outcomes
All-cause mortality 862 405
All-cause mortality and DDKF 1046 634
DDKF 766 293
CV outcomes (CV death, MI, RSD, stroke) 792 319
Mortality and CV outcomes 963 529
Total subjects 1131 737
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